Glutathione is among the important antioxidants to prevent oxidative stress. However, the relationships between abnormality in the glutathione system and pathophysiology of schizophrenia remain uncertain due to inconsistent findings on glutathione levels and/or glutathione-related enzyme activities in patients with schizophrenia.
Methods:
A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies, in which three metabolite levels (glutathione, glutathione disulfide, and total glutathione (glutathione+glutathione disulfide)) and five enzyme activities (glutathione peroxidase, glutathione reductase, glutamate-cysteine ligase, glutathione synthetase, and glutathione S-transferase) were measured with any techniques in both patients with schizophrenia and healthy controls, were included. Standardized mean differences were calculated to determine the group differences in the glutathione levels with a random-effects model.
Results:
We identified 41, 9, 15, 38, and seven studies which examined glutathione, glutathione disulfide, total glutathione, glutathione peroxidase, and glutathione reductase, respectively. Patients with schizophrenia had lower levels of both glutathione and total glutathione and decreased activity of glutathione peroxidase compared to controls. Glutathione levels were lower in unmedicated patients with schizophrenia than those in controls while glutathione levels did not differ between patients with first-episode psychosis and controls.
Conclusions:
Our findings suggested that there may be glutathione deficits and abnormalities in the glutathione redox cycle in patients with schizophrenia. However, given the small number of studies examined the entire glutathione system, further studies are needed to elucidate a better understanding of disrupted glutathione function in schizophrenia, which may pave the way for the development of novel therapeutic strategies in this disorder.
AbdallaDSMonteiroHPOliveiraJA, et al. (1986) Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patient. Clin Chem32: 805–807.
2.
AkyolOHerkenHUzE, et al. (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry26: 995–1005.
3.
Al-AsmariAKKhanMW (2014) Inflammation and schizophrenia: Alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol33: 115–122.
4.
AlamedaLFournierMKhadimallahI, et al. (2018) Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. Proc Natl Acad Sci USA115: 12495–12500.
5.
AltuntasIAksoyHCoskunI, et al. (2000) Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med38: 1277–1281.
6.
AnHDuXHuangX, et al. (2018) Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl Psychiatry8: 258.
7.
AtmacaMTezcanEKulogluM, et al. (2005) The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci59: 652–656.
8.
AzadGKTomarRS (2014) Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways. Mol Biol Rep41: 4865–4879.
9.
BaiZLLiXSChenGY, et al. (2018) Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci66: 428–436.
10.
BallesterosAJiangPSummerfeltA, et al. (2013a) No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr Res146: 184–189.
11.
BallesterosASummerfeltADuX, et al. (2013b) Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol124: 2209–2215.
12.
BarakAJHumollerFLStevensJD (1958) Blood glutathione levels in the male schizophrenic patient. AMA Arch Neurol Psychiatry80: 237–240.
13.
BarbosaMQQueirogaRBertozzoC, et al. (2018) Effect of diets with goat milk fat supplemented with exercise on anxiety and oxidative stress in the brains of adult rats. Food Funct9: 2891–2901.
14.
BaumannPSGriffaAFournierM, et al. (2016) Impaired fornix-hippocampus integrity is linked to peripheral glutathione peroxidase in early psychosis. Transl Psychiatry6: e859.
15.
BaxterPSBellKFHaselP, et al. (2015) Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun6: 6761.
16.
Ben OthmenLMechriAFendriC, et al. (2008) Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry32: 155–159.
17.
BerkMMalhiGSGrayLJ, et al. (2013) The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci34: 167–177.
18.
BorensteinMHedgesLVHigginsJP, et al. (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods1: 97–111.
19.
BrandtASUnschuldPGPradhanS, et al. (2016) Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla. Schizophr Res172: 101–105.
20.
CabungcalJHCounotteDSLewisE, et al. (2014) Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron83: 1073–1084.
21.
CalverARHallACYuWP, et al. (1998) Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron20: 869–882.
22.
ConusPSeidmanLJFournierM, et al. (2018) N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophr Bull44: 317–327.
23.
DadheechGMishraSGautamS, et al. (2006) Oxidative stress, alpha-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J Clin Biochem21: 34–38.
24.
DadheechGSharmaPGautamS (2012) Oxidative stress-induced response of some endogenous antioxidants in schizophrenia. Indian J Clin Biochem27: 278–283.
25.
DasTKJavadzadehADeyA, et al. (2018) Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. Prog Neuropsychopharmacol Biol Psychiatry. Epub ahead of print 17 August 2018. doi: 10.1016/j.pnpbp.2018.08.006.
26.
de la Fuente-SandovalCReyes-MadrigalFMaoX, et al. (2015) Cortico-Striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. Int J Neuropsychopharmacol19: pyv105.
27.
DeponteM (2013) Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta1830: 3217–3266.
28.
Dietrich-MuszalskaAOlasBGlowackiR, et al. (2009) Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology59: 1–7.
29.
DikenHKelleMTumerC, et al. (2001) Effects of cigarette smoking on blood antioxidant status in short-term and Long-Term Smokers. Turk J Med Sci31: 553–557.
30.
DoKQCabungcalJHFrankA, et al. (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol19: 220–230.
31.
DoKQCuenodMHenschTK (2015) Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia. Schizophr Bull41: 835–846.
32.
DoKQTrabesingerAHKirsten-KrugerM, et al. (2000) Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci12: 3721–3728.
33.
DuvalSTweedieR (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics56: 455–463.
34.
EggerMDavey SmithGSchneiderM, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ315: 629–634.
35.
EvansDRParikhVVKhanMM, et al. (2003) Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids69: 393–399.
36.
FlatowJBuckleyPMillerBJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry74: 400–409.
37.
FlynnSWLangDJMackayAL, et al. (2003) Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry8: 811–820.
38.
FormanHJZhangHRinnaA (2009) Glutathione: Overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med30: 1–12.
39.
FraguasDDiaz-CanejaCMAyoraM, et al. (2018) Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis. Schizophr Bull. Epub ahead of print 28 August 2018. doi: 10.1093/schbul/sby125.
40.
FraguasDDiaz-CanejaCMRodriguez-QuirogaA, et al. (2017) Oxidative stress and inflammation in early onset first episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol20: 435–444.
41.
GawrylukJWWangJFAndreazzaAC, et al. (2011) Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol14: 123–130.
42.
Gonzalez-BurgosGLewisDA (2012) NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull38: 950–957.
43.
Gonzalez-LiencresCTasCBrownEC, et al. (2014) Oxidative stress in schizophrenia: A case-control study on the effects on social cognition and neurocognition. BMC Psychiatry14: 268.
44.
GysinRKraftsikRBoulatO, et al. (2011) Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal15: 2003–2010.
45.
GysinRKraftsikRSandellJ, et al. (2007) Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci USA104: 16621–16626.
46.
GysinRRiedererIMCuenodM, et al. (2009) Skin fibroblast model to study an impaired glutathione synthesis: Consequences of a genetic polymorphism on the proteome. Brain Res Bull79: 46–52.
47.
HardinghamGEDoKQ (2016) Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci17: 125–134.
48.
HerkenHUzEOzyurtH, et al. (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry6: 66–73.
49.
HigginsJPTGreenS (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
50.
HigginsJPThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med21: 1539–1558.
51.
HofPRHaroutunianVFriedrichVLJr., et al. (2003) Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry53: 1075–1085.
52.
HoftmanGDVolkDWBazmiHH, et al. (2015) Altered cortical expression of GABA-related genes in schizophrenia: Illness progression vs developmental disturbance. Schizophr Bull41: 180–191.
53.
IvanovaSASmirnovaLPShchigorevaYG, et al. (2015) Serum glutathione in patients with schizophrenia in dynamics of antipsychotic therapy. Bull Exp Biol Med160: 283–285.
54.
JonesDPCarlsonJLSamiecPS, et al. (1998) Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta275: 175–184.
55.
JordanWDobrowolnyHBahnS, et al. (2018) Oxidative stress in drug-naive first episode patients with schizophrenia and major depression: Effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci268: 129–143.
56.
KannanRKuhlenkampJFJeandidierE, et al. (1990) Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest85: 2009–2013.
57.
KartalciSKarabulutABOzcanAC, et al. (2011) Acute and chronic effects of electroconvulsive treatment on oxidative parameters in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry35: 1689–1694.
58.
KimSKKangSWChungJH, et al. (2015) Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1)and schizophrenia risk: A meta-analysis. Int J Mol Sci16: 19602–19611.
59.
KimSYParkJELeeYJ, et al. (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol66: 408–414.
60.
KlauserPXinLFournierM, et al. (2018) N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: A double-blind randomized placebo-controlled trial. Transl Psychiatry8: 220.
61.
KohrGEckardtSLuddensH, et al. (1994) NMDA receptor channels: Subunit-specific potentiation by reducing agents. Neuron12: 1031–1040.
62.
KulakACuenodMDoKQ (2012) Behavioral phenotyping of glutathione-deficient mice: Relevance to schizophrenia and bipolar disorder. Behav Brain Res226: 563–570.
63.
KulogluMUstundagBAtmacaM, et al. (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct20: 171–175.
64.
KumarJLiddleEBFernandesCC, et al. (2018) Glutathione and glutamate in schizophrenia: A 7T MRS study. Mol Psychiatry. Epub ahead of print 22 June 2018. doi: 10.1038/s41380-018-0104-7.
65.
LangbeinKHesseJGussewA, et al. (2017) Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naive first-episode psychosis patients. Prostaglandins Leukot Essent Fatty Acids. Epub ahead of print 18 October 2017
66.
LashLHJonesDP (1985) Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma. Arch Biochem Biophys240: 583–592.
67.
LiHCChenQZMaY, et al. (2006) Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. J Zhejiang Univ Sci B7: 981–986.
68.
LooneyJMChildsHM (1934) The lactic acid and glutathione content of the blood of schizophrenic patients. J Clin Invest13: 963–968.
69.
LuSC (2009) Regulation of glutathione synthesis. Mol Aspects Med30: 42–59.
70.
MaasDAVallesAMartensGJM (2017) Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry7: e1171.
71.
Martinez-CengotitabengoaMMac-DowellKSLezaJC, et al. (2012) Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res137: 66–72.
72.
Martinez-CengotitabengoaMMicoJAArangoC, et al. (2014) Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophr Res156: 23–29.
73.
MatsuzawaDObataTShirayamaY, et al. (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: A 3T 1H-MRS study. PLoS One3: e1944.
74.
MicoJARojas-CorralesMOGibert-RaholaJ, et al. (2011) Reduced antioxidant defense in early onset first-episode psychosis: A case-control study. BMC Psychiatry11: 26.
75.
MiljevicCNikolic-KokicASaicicZS, et al. (2010a) Correlation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication. Psychiatry Res178: 68–72.
76.
MiljevicCNikolicMNikolic-KokicA, et al. (2010b) Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry34: 303–307.
77.
MiljevicCDNikolic-KokicABlagojevicD, et al. (2018) Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res269: 746–752.
78.
MillsBJLangCA (1996) Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol52: 401–406.
79.
MoninABaumannPSGriffaA, et al. (2015) Glutathione deficit impairs myelin maturation: Relevance for white matter integrity in schizophrenia patients. Mol Psychiatry20: 827–838.
80.
MukherjeeSMahadikSPSchefferR, et al. (1996) Impaired antioxidant defense at the onset of psychosis. Schizophr Res19: 19–26.
81.
NakajimaSTakeuchiHPlitmanE, et al. (2015) Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr Res164: 164–175.
82.
NordbergJArnerES (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med31: 1287–1312.
83.
NuciforaLGTanakaTHayesLN, et al. (2017) Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry7: e1215.
84.
O’DonnellPLewisBLWeinbergerDR, et al. (2002) Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex12: 975–982.
85.
ParelladaMMorenoCMac-DowellK, et al. (2012) Plasma antioxidant capacity is reduced in Asperger syndrome. J Psychiatr Res46: 394–401.
86.
PavlovićDTamburićVStojanovićI, et al. (2002) Oxidative stress as marker of positive symptoms in schizophrenia. Med Biol9: 157–161.
87.
PeckhamNHChoiBH (1988) Abnormal neuronal distribution within the cerebral cortex after prenatal methylmercury intoxication. Acta Neuropathol76: 222–226.
88.
PlitmanEde la Fuente-SandovalCReyes-MadrigalF, et al. (2016a) Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: A proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull42: 415–424.
89.
PlitmanENakajimaSde la Fuente-SandovalC, et al. (2014) Glutamate-mediated excitotoxicity in schizophrenia: A review. Eur Neuropsychopharmacol24: 1591–1605.
90.
PlitmanEPatelRChungJK, et al. (2016b) Glutamatergic metabolites, volume and cortical thickness in antipsychotic-naive patients with first-episode psychosis: Implications for excitotoxicity. Neuropsychopharmacology41: 2606–2613.
91.
Quincozes-SantosABoberminLDTonialRP, et al. (2010) Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions. Eur Arch Psychiatry Clin Neurosci260: 475–481.
92.
RaeCDWilliamsSR (2017) Glutathione in the human brain: Review of its roles and measurement by magnetic resonance spectroscopy. Anal Biochem529: 127–143.
93.
RaffaMAtigFMhallaA, et al. (2011) Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry11: 124.
94.
RaffaMBarhoumiSAtigF, et al. (2012a) Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry39: 371–375.
95.
RaffaMFendriCBen OthmenL, et al. (2012b) The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry39: 52–56.
96.
RaffaMJradBBHKhelilAH, et al. (2016) Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with schizophrenia: A case-control study in a Tunisian population. Gene Reports4: 249–252.
97.
RaffaMMechriAOthmanLB, et al. (2009) Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry33: 1178–1183.
98.
RajjiTKMirandaDMulsantBH (2014) Cognition, function, and disability in patients with schizophrenia: A review of longitudinal studies. Can J Psychiatry59: 13–17.
99.
RanjekarPKHingeAHegdeMV, et al. (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res121: 109–122.
100.
RavikumarAArunPDeviKV, et al. (2000) Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol38: 438–446.
101.
ReddyRSahebaraoMPMukherjeeS, et al. (1991) Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry30: 409–412.
102.
ReidMASalibiNWhiteDM, et al. (2019) 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull45: 180–189.
103.
ReyazuddinMAzmiSAIslamN, et al. (2014) Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J Psychiatry56: 344–349.
104.
RichardsonWDPringleNMosleyMJ, et al. (1988) A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell53: 309–319.
105.
RowlandLMPradhanSKorenicS, et al. (2016a) Elevated brain lactate in schizophrenia: A 7 T magnetic resonance spectroscopy study. Transl Psychiatry6: e967.
106.
RowlandLMSummerfeltAWijtenburgSA, et al. (2016b) Frontal Glutamate and gamma-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry73: 166–174.
107.
SamuelssonMSkoghELundbergK, et al. (2013) Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia. Psychiatry Res210: 819–824.
108.
SamuelssonMVainikkaLOllingerK (2011) Glutathione in the blood and cerebrospinal fluid: A study in healthy male volunteers. Neuropeptides45: 287–292.
109.
SarandolAKirliSAkkayaC, et al. (2007) Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry31: 1164–1169.
110.
SarandolASarandolEAcikgozHE, et al. (2015) First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment. Psychiatry Clin Neurosci69: 699–707.
111.
SeeligGFSimondsenRPMeisterA (1984) Reversible dissociation of gamma-glutamylcysteine synthetase into two subunits. J Biol Chem259: 9345–9347.
112.
SimsekSGencoglanSYukselT, et al. (2016) Oxidative stress and DNA damage in untreated first-episode psychosis in adolescents. Neuropsychobiology73: 92–97.
113.
SrivastavaNBarthwalMKDalalPK, et al. (2001) Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl)158: 140–145.
114.
StarkAKUylingsHBSanz-ArigitaE, et al. (2004) Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry161: 882–888.
115.
SteulletPCabungcalJHKulakA, et al. (2010) Redox dysregulation affects the ventral but not dorsal hippocampus: Impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci30: 2547–2558.
116.
SteulletPCabungcalJHMoninA, et al. (2016) Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?Schizophr Res176: 41–51.
117.
SteulletPNeijtHCCuenodM, et al. (2006) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience137: 807–819.
118.
TaylorROsuchEASchaeferB, et al. (2017) Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T. BJPsych Open3: 6–11.
119.
TerpstraMVaughanTJUgurbilK, et al. (2005) Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: Application to schizophrenia. MAGMA18: 276–282.
120.
TharoorHMaraSGopalS (2018) Role of novel dietary supplement N-acetyl cysteine in treating negative symptoms in schizophrenia: A 6-month follow-up study. Indian J Psychol Med40: 139–142.
121.
TsengKYLewisBLHashimotoT, et al. (2008) A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci28: 12691–12699.
122.
TuncelOKSarisoyGBilgiciB, et al. (2015) Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res228: 688–694.
123.
WangAMPradhanSCoughlinJM, et al. (2019) Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis. JAMA Psychiatry. Epub ahead of print 9 January 2019. doi: 10.1001/jamapsychiatry.2018.3637.
124.
WangAYLohmannKMYangCK, et al. (2011) Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol122: 615–626.
125.
WijtenburgSAWrightSNKorenicSA, et al. (2017) Altered glutamate and regional cerebral blood flow levels in schizophrenia: A (1)H-MRS and pCASL study. Neuropsychopharmacology42: 562–571.
126.
WilliamsS (2010) Gamma oscillations and schizophrenia. J Psychiatry Neurosci35: 75–77.
127.
WoodSJBergerGEWellardRM, et al. (2009) Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation. Neurobiol Dis33: 354–357.
XinLMekleRFournierM, et al. (2016) Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophr Bull42: 1185–1196.
130.
YaoJKKeshavanMS (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid Redox Signal15: 2011–2035.
131.
YaoJKLeonardSReddyR (2006) Altered glutathione redox state in schizophrenia. Dis Markers22: 83–93.
132.
YaoJKReddyRMcElhinnyLG, et al. (1998) Effects of haloperidol on antioxidant defense system enzymes in schizophreniaJ Psychiatr Res32: 385–391.
133.
YapislarH (2012) Altered erythrocyte deformability and antioxidant status in patients with schizophrenia. Marmara Medical Journal25: 133–137.
134.
ZakiSMAbdel FattahSHassanDS (2019) The differential effects of high-fat and high fructose diets on the liver of male albino rat and the proposed underlying mechanisms. Folia Morphol (Warsz)78: 124–136.
135.
ZhangMZhaoZHeL, et al. (2010) A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci53: 112–124.
136.
ZhangXYChenDCTanYL, et al. (2015) The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology51: 201–208.
137.
ZhangXYTanYLCaoLY, et al. (2006) Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res81: 291–300.
138.
ZhangXYTanYLZhouDF, et al. (2007) Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry68: 754–760.
139.
ZhangYCattsVSShannon WeickertC (2017) Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust N Z J Psychiatry52: 690–698.
140.
ZhengWZhangQECaiDB, et al. (2018) N-acetylcysteine for major mental disorders: A systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand137: 391–400.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
